Abhaya Kumar

Abhaya Kumar, MD at Shasun Pharmaceuticals said the company's merger with Strides will be completed as soon as court approvals of the latter are in place. He is sure the merged entity will be effective from April 1 2015 itself.

Expect revenue of around Rs 400 cr in Q4: Shasun Pharma

Abhaya Kumar of Shasun Pharma believes Q4 is always a better quarter and hopes to maintain revenue growth and EBITDA at around current levels.

Shasun Pharma eyes robust Q4 growth, says MD

Abhaya Kumar, MD of Shasun Pharmaceuticals said the Q3 margins were stressed owing to price pressures from the US.

UK biz strong; see FY13 revenue at Rs 1,200cr: Shashun

Shasun Pharma is one of the key suppliers to Vertex for Hepatitis C drug -Incivek, which has received a US Food & Drug Administration (USFDA) 'Black Box' warning. This warning indicates that if one gets severe rash symptoms then the drug should be stopped using immediately.

Shasun Pharma plans Rs 250cr expansion

In an interview to CNBC-TV18, Abhaya Kumar, managing director of Shasun Pharmaceuticals says, the company has huge expansion plans. “Shasun is on a very high expansion spree now, investing more than Rs 250 crore in Vizag and in other places. We have raised Rs 50 crore,” he adds.

Shasun Pharma expects 40-50% topline growth in FY12

Abhaya Kumar, managing director of Shasun Pharmaceuticals expects the company's topline to grow 40-50% in FY12. He told CNBC-TV18 in an interview that their confirmed orders for third and fourth quarter are very strong.